TrialsgrambetaRCTs are beautiful

LINC-3

2020

Osilodrostat in Cushing's Disease (LINC-3)

In 137 adults with Cushing's disease, osilodrostat achieved control of mean 24-h urinary free cortisol in a randomised-withdrawal phase versus placebo.

Result

Efficacy: Maintained mUFC control during 8-week withdrawalOR 13.7 · P < 0.0001

Below 1 favours placebo, above 1 favours osilodrostat.

Event rates
Absolute difference
57 points
NNT
2

Absolute difference and NNT are derived from the event rates.

Original publication
Subtopic
Cushing's disease
Design
Phase 3 with randomised withdrawal at week 26
Relevance
Supporting: context rather than must-know.
Source
Pivonello R, et al. Lancet Diabetes Endocrinol. 2020;8(9):748-761.doi 10.1016/S2213-8587(20)30240-0

Discussion & critique

Basis of the Isturisa approval for Cushing's disease: oral steroidogenesis inhibitor with predictable cortisol-lowering.